Michael T Black

Summary

Publications

  1. ncbi Novel target sites in bacteria for overcoming antibiotic resistance
    Michael T Black
    Novexel SA, Parc Biocitech, 102 route de Noisy, 93230 Romainville, France
    Adv Drug Deliv Rev 57:1528-38. 2005
  2. ncbi Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases
    Michael T Black
    Novexel SA, Parc Biocitech, Romainville, France
    Antimicrob Agents Chemother 52:3339-49. 2008
  3. ncbi New inhibitors of bacterial topoisomerase GyrA/ParC subunits
    Michael T Black
    Novexel SA, Parc Biocitech, 102 Avenue Gaston Roussel, Romainville, France
    Curr Opin Investig Drugs 10:804-10. 2009
  4. ncbi Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor
    Thérèse Stachyra
    Novexel SA, Parc Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
    Antimicrob Agents Chemother 54:5132-8. 2010
  5. ncbi In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates
    Premavathy Levasseur
    Novexel SA, Parc Biocitech, Romainville, France
    Antimicrob Agents Chemother 56:1606-8. 2012
  6. ncbi In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
    Thérèse Stachyra
    Novexel SA, Parc Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
    J Antimicrob Chemother 64:326-9. 2009

Collaborators

  • Jean Marie Frere
  • Thérèse Stachyra
  • Premavathy Levasseur
  • Monique Claudon
  • Christine Miossec
  • Kenneth Coleman
  • Anne Marie Girard
  • Marie Claude Péchereau
  • Herman Goossens
  • Jean Michel Bruneau

Detail Information

Publications6

  1. ncbi Novel target sites in bacteria for overcoming antibiotic resistance
    Michael T Black
    Novexel SA, Parc Biocitech, 102 route de Noisy, 93230 Romainville, France
    Adv Drug Deliv Rev 57:1528-38. 2005
    ..What are the reasons for the differences between expectations and reality? This article reviews what has been achieved in the exploitation of bacterial genomes for the discovery of novel antibacterials...
  2. ncbi Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases
    Michael T Black
    Novexel SA, Parc Biocitech, Romainville, France
    Antimicrob Agents Chemother 52:3339-49. 2008
    ..Certain combinations of mutations giving rise to NXL101 resistance and those giving rise to fluoroquinolone resistance may be mutually exclusive...
  3. ncbi New inhibitors of bacterial topoisomerase GyrA/ParC subunits
    Michael T Black
    Novexel SA, Parc Biocitech, 102 Avenue Gaston Roussel, Romainville, France
    Curr Opin Investig Drugs 10:804-10. 2009
    ..The merits of the most prominent novel antibiotics that have reached, or are expected to reach the clinical phase of drug development are summarized in this review...
  4. ncbi Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor
    Thérèse Stachyra
    Novexel SA, Parc Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
    Antimicrob Agents Chemother 54:5132-8. 2010
    ..In-depth studies on TEM-1 and P99 demonstrated that NXL104 had a comparable or better affinity and inactivation rate than clavulanate and tazobactam and in all cases an improved stability of the covalent enzyme/inhibitor complex...
  5. ncbi In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates
    Premavathy Levasseur
    Novexel SA, Parc Biocitech, Romainville, France
    Antimicrob Agents Chemother 56:1606-8. 2012
    ..Ceftazidime-avibactam also demonstrated better antipseudomonal activity than imipenem (82% susceptibility), a common reference treatment...
  6. ncbi In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
    Thérèse Stachyra
    Novexel SA, Parc Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
    J Antimicrob Chemother 64:326-9. 2009
    ..The activity of NXL104 against KPC beta-lactamases was examined...